BSI recognized for innovative in-lab process that sustainably scales its gold standard solutions for human and plant health.

Botanical Solution Inc. (BSI), has been named winner of the 2023 Best Process Innovation Award from ICIS Chemical Business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231023605215/en/

Botanical Solution Inc. (BSI) has received the 2023 Best Process Innovation Award from ICIS Chemical Business for BSI's innovative in-lab process that sustainably scales gold standard solutions for human and plant health. The Award was presented in an October 17 ceremony at the Savoy Hotel in London and accepted by Laura Reilly, Croda Pharma VP Marketing. Croda Pharma announced its partnership with BSI earlier this year and launched this award-winning innovation subsequently to their global customer base. (Photo: Business Wire)

The ICIS Award for Process Innovation recognizes BSI’s “unique and proprietary platform for a truly sustainable and scalable production of plant-based products without sourcing raw materials from nature or conventional plantations,” and its impact, which has given birth to two gold standard products for human and plant health.

BSI’s most recent technology breakthrough enables a robust supply chain for the vaccine adjuvant QS-21, thanks to a partnership with Croda Pharma This next generation of QS-21, has been proven biochemically comparable and as immunogenic as the traditional QS-21, obtained from very old soapbark trees that grow predominantly in Chile. QS-21 is used in FDA approved vaccines such as shingles, malaria, RSV, and COVID plus promising new vaccine candidates and immunotherapy treatments such as cancer. Croda Pharma announced the partnership with BSI earlier this year and launched this award-winning innovation subsequently to their global customer base

Meanwhile, the award winning biopesticide Quillibrium®, under a successful partnership with Syngenta established since 2019, has produced over 50% YOY growth of effective growers’ adoption of the product in Chile and Peru, accumulating over 100,000 acres treated to date. Even greater adoption is expected as Quillibrium® expansion plan materializes in Mexico, Brazil, the US and EU.

The ICIS Award Ceremony took place October 17 at the Savoy Hotel in Central London. Accepting the 2023 Process Innovation Award on behalf of BSI was Laura Reilly, Croda Pharma’s VP Marketing, who stated, “I’m honored to accept this Award on behalf of Croda’s partner, Botanical Solution. Croda and BSI have an excellent partnership to meet the pharma industry’s needs for QS-21, including a reliable and stable supply of this Gold Standard vaccine adjuvant.”

BSI CEO Gastón Salinas, stated, “The BSI team is proud that our contribution to human health and sustainable agriculture is receiving this high recognition from the industry. We thank the ICIS Chemical Business team of judges for this honor, as well as our great collaborators Croda Pharma and Syngenta for their valued partnership.”

About BSI

BSI, a Delaware Corporation has a proprietary R&D platform for truly sustainable and improved production of consistent and high-quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a tissue cultured plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI’s biopesticide Quillibrium® and the adjuvant QS-21, used in modern vaccine development. To learn more visit us at www.botanical-solution.com.

About ICIS

ICIS Chemical Business is an independent chemical and energy market intelligence company, connecting data, markets and partners to optimize business decision making.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231023605215/en/